🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Purdue Pharma judge extends Sacklers' U.S. litigation shield to Feb 17

Published 02/01/2022, 11:46 AM
Updated 02/01/2022, 01:10 PM
© Reuters. FILE PHOTO: Bottles of prescription painkiller OxyContin pills, made by Purdue Pharma LP sit on a counter at a local pharmacy in Provo, Utah, U.S., April 25, 2017.  REUTERS/George Frey

By Dietrich Knauth and Tom Hals

(Reuters) - A federal judge on Tuesday extended a legal shield protecting the Sackler family owners of Purdue Pharma from lawsuits to Feb. 17, as they try to reach a deal with several states to settle sprawling litigation stemming from the U.S. opioid crisis.

U.S. Bankruptcy Judge Robert Drain said allowing the legal shield to expire at the end of Tuesday would be "quite foolish," given the mediator's report of a possible deal.

Purdue, maker of the highly addictive OxyContin opioid painkiller, filed for bankruptcy in 2019 in the face of thousands of lawsuits accusing it and the Sacklers of fueling an American opioid epidemic through deceptive marketing.

The opioid abuse crisis has led to nearly 500,000 overdose deaths over two decades, according to U.S. data.

Members of the Sackler family have denied the allegations.

Purdue’s bankruptcy judge has paused litigation against members of the Sackler family since 2019, seeking to buy time for the company to pursue a reorganization in bankruptcy court.

On Monday, the mediator reported that the Sacklers were nearing an agreement to boost their more than $4.3 billion cash contribution to resolve the litigation after negotiating with states that objected to the original terms.

Judge Drain said on Tuesday that "all bets were open" as to whether the Sacklers would continue to receive legal protection from opioid lawsuits if the current round of mediation does not result in a new deal.

If the Sacklers’ legal protection were allowed to expire, the family and Purdue would be swept up in a "a firestorm of uncoordinated litigation" that would destroy any value the company has left, Purdue attorney Marshall Huebner told the judge on Tuesday.

Legal protections for the Sacklers have been a point of controversy throughout Purdue’s bankruptcy.

The current round of mediation began in January, after a U.S. district judge ruled that Purdue’s bankruptcy reorganization plan improperly shielded Sackler family members, who had not filed for Chapter 11 themselves, from opioid litigation.

© Reuters. FILE PHOTO: Bottles of prescription painkiller OxyContin pills, made by Purdue Pharma LP sit on a counter at a local pharmacy in Provo, Utah, U.S., April 25, 2017.  REUTERS/George Frey

Attorney Joe Rice, who represents plaintiffs who have sued Purdue and the Sackler family, said in court on Tuesday that the legal protections should be allowed to expire.

Allowing lawsuits to proceed could break a holding pattern that "only benefits the Sackler family," Rice said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.